Sage Therapeutics (SAGE) : The most positive equity analysts on Sage Therapeutics (SAGE) expects the shares to touch $121, whereas, the least positive believes that the stock will trade at $18 in the short term. The company is covered by 7 Wall Street Brokerage Firms. The average price target for shares are $75.14 with an expected fluctuation of $33.18 from the mean.
Sage Therapeutics (SAGE) has witnessed a rise of 20.3% or 632,879 shares in its short figure. The short interest augmentation took it from 3,114,254 on June 15,2016 to 3,747,133 on June 30,2016. In terms of floated shares, the short interest was calculated to be 14.8%. The days to cover are 6 given that the daily volume averaged 661,827 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 12th.
Also, BMO Capital initiates coverage on Sage Therapeutics (NASDAQ:SAGE). The shares have now been rated Outperform by the stock experts at the ratings house. The rating by the firm was issued on June 29, 2016.
Sage Therapeutics (NASDAQ:SAGE): On Thursdays trading session , Opening price of the stock was $43.43 with an intraday high of $43.64. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $39.8. However, the stock managed to close at $41.88, a loss of 1.30% for the day. On the previous day, the stock had closed at $42.43. The total traded volume of the day was 2,314,972 shares.
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat life-threatening, rare central nervous system (CNS) disorders. The Companys lead product candidate in its status epilepticus (SE) program is SAGE-547. SAGE-689 and SAGE-217 are two additional product candidates in its pipeline. The Company has submitted investigational new drug (IND) for SAGE-547 for the treatment of SRSE with the United States Food and Drug Administration. SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors. SAGE-217 is a neuroactive steroid that acts as a positive allosteric modulator of synaptic and extra-synaptic GABAA receptor subtypes. SAGE-689 is being developed as an adjunctive IV therapy for the treatment of status epilepticus patients.